Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Metabolomics of intensive weight management clinic (IWMC) weight loss (Study ST000744)

C18 NEGATIVE ION MODE (Analysis AN001165)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10
PE 32:1; [M-H]-@6.23	ME206606	1.71	0.99	2.02	0.78	0.88	0.57	0.32	0.43	0.51	1.25
PE 33:1; [M-H]-@6.53	ME206607	1.42	0.84	2.34	0.57	0.91	0.53	0.41	0.60	0.35	1.43
PE 36:5; [M-H]-@5.94	ME206619	1.23	0.67	2.14	0.85	0.67	0.93	0.63	0.93	0.45	0.70
PE 37:6; [M-H]-@5.94	ME206623	1.03	0.65	2.51	0.89	0.52	0.64	0.46	0.68	0.64	0.98
PE 34:3; [M-H]-@5.95	ME206610	1.25	0.97	2.30	0.91	0.75	0.62	0.48	0.49	0.58	0.78
PE 35:4; [M-H]-@6.04	ME206613	1.10	1.25	2.24	0.84	0.80	0.56	0.49	0.43	0.67	0.86
plasmenyl-PE 36:5; [M-H]-@6.27	ME206665	0.73	0.57	0.93	1.07	0.97	1.00	1.23	2.02	0.78	0.73
PC 34:5; [M-Ac-H]-@5.14	ME206577	0.97	0.30	1.15	1.21	1.16	0.62	0.67	1.88	1.17	0.64
PC 36:6; [M-Ac-H]-@5.48	ME206587	0.72	0.53	1.22	1.44	0.93	0.75	0.66	1.91	0.69	0.65
PE 36:6; [M-H]-@5.60	ME206620	0.71	1.24	1.63	0.73	0.94	0.62	1.44	0.33	0.70	1.53
PE 37:3; [M-H]-@6.86	ME206621	0.87	1.64	1.38	1.15	0.74	0.43	1.02	0.65	0.94	1.05
PE 35:2; [M-H]-@6.68	ME206612	1.18	1.60	1.08	0.66	0.55	0.77	1.74	0.71	0.72	1.59
CerP 34:1; [M-H]-@5.83	ME206545	0.88	0.91	1.03	0.96	0.82	0.87	1.17	1.00	1.24	1.28
plasmenyl-PE 34:1; [M-H]-@7.15	ME206661	0.70	0.88	0.82	0.96	0.98	1.02	1.50	1.12	1.11	1.14
plasmenyl-PE 42:5; [M-H]-@7.85	ME206675	0.93	1.00	0.99	0.84	0.71	0.99	1.57	1.17	0.98	1.14
FFA(24:2)	ME206561	0.89	0.91	0.72	0.78	0.93	1.05	2.16	0.99	1.17	0.92
plasmenyl-PE 40:3; [M-H]-@8.01	ME206672	1.00	1.09	0.84	0.81	0.65	0.87	1.97	0.73	1.15	1.48
plasmenyl-PE 40:4; [M-H]-@7.72	ME206673	0.94	0.91	0.80	0.80	0.61	1.15	1.87	0.94	0.93	1.57
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.83	ME206564	0.75	1.29	0.78	1.17	0.97	0.88	1.11	0.91	1.45	0.80
PC 37:2; [M-Ac-H]-@7.22	ME206588	0.52	1.18	0.82	1.47	0.98	0.75	1.09	1.12	1.10	0.82
PA 34:2; [M-H]-@6.26	ME206566	0.93	1.64	0.76	1.15	1.04	0.94	0.86	1.02	0.94	0.83
PC 35:1; [M-Ac-H]-@7.04	ME206578	0.83	1.46	0.97	0.93	1.17	0.96	0.82	1.01	0.89	1.00
PE 36:2; [M-H]-@6.97	ME206616	1.22	1.57	1.18	0.95	1.07	0.79	0.59	0.75	0.79	1.02
PI 34:2; [M-H]-@5.30	ME206641	1.19	1.42	1.27	1.02	0.98	0.96	0.44	0.78	0.97	0.71
PI 40:6; [M-H]-@5.83	ME206649	1.08	0.79	1.27	0.79	1.21	1.08	0.57	1.12	1.28	0.62
PC 35:5; [M-Ac-H]-@5.51	ME206581	1.03	0.71	1.16	1.24	1.14	0.43	1.11	1.15	0.76	1.08
PC 39:6; [M-Ac-H]-@6.40	ME206598	0.79	0.61	1.22	1.02	1.22	0.94	1.13	1.10	0.72	0.92
PE 37:5; [M-H]-@6.14	ME206622	0.98	0.87	1.05	0.78	1.19	1.09	0.84	1.48	0.84	0.93
PC 39:5; [M-Ac-H]-@6.61	ME206597	0.69	0.78	0.96	1.40	1.14	0.60	1.03	1.48	1.03	0.66
PC 36:5; [M-Ac-H]-@5.68	ME206586	0.85	0.60	1.08	1.12	0.95	1.05	0.95	1.61	0.82	0.77
PC 38:7; [M-Ac-H]-@5.51	ME206596	0.83	0.86	1.07	1.23	0.94	0.88	0.92	1.37	0.96	0.71
FFA(24:3)	ME206562	0.98	0.56	0.71	1.11	1.02	1.43	0.71	0.90	1.27	1.26
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.90	ME206565	0.97	0.94	0.85	1.03	1.08	1.05	0.68	0.85	1.33	1.24
PC 40:8; [M-Ac-H]-@5.79	ME206604	1.03	1.20	0.86	0.96	0.84	0.99	0.58	1.05	1.41	1.34
PE 38:4; [M-H]-@6.93	ME206626	1.19	0.85	1.23	0.98	1.00	0.88	0.83	0.83	0.89	1.16
PG 33:0; [M-H]-@6.08	ME206637	1.43	0.83	1.15	0.95	0.77	0.98	0.81	0.94	1.03	1.14
PC 33:1; [M-Ac-H]-@6.43	ME206571	1.40	1.27	0.97	0.93	1.02	0.96	1.05	0.84	0.88	0.79
PI 36:4; [M-H]-@5.27	ME206644	1.25	1.29	0.94	0.96	1.02	1.12	0.77	0.86	0.95	0.89
FFA(22:0)	ME206555	1.32	1.00	0.89	1.01	1.10	1.00	0.83	0.99	0.86	1.04
FFA(24:0)	ME206559	1.60	0.89	0.84	1.04	1.11	1.01	0.74	0.80	0.98	1.05
PE 38:2; [M-H]-@7.50	ME206624	0.83	1.06	0.89	1.46	0.75	0.85	0.71	1.20	1.08	1.01
PC 35:3; [M-Ac-H]-@6.10	ME206580	1.04	0.90	0.84	1.34	0.82	1.06	0.91	0.82	0.98	1.17
plasmenyl-PE 38:1; [M-H]-@8.22	ME206666	1.12	0.83	0.96	1.34	0.65	0.81	1.02	0.90	1.07	1.26
PC 38:4; [M-Ac-H]-@6.73	ME206593	0.83	0.69	1.11	1.32	1.11	0.92	0.75	0.90	0.92	1.01
PC 36:4; [M-Ac-H]-@6.09	ME206585	0.79	0.65	1.18	1.14	1.12	0.92	0.68	0.88	1.23	1.05
PC 37:6; [M-Ac-H]-@5.79	ME206590	0.81	0.71	1.18	1.12	1.01	0.93	0.67	1.07	1.21	1.00
PC 38:6; [M-Ac-H]-@6.01	ME206595	0.74	0.63	1.02	1.09	1.09	1.04	0.88	1.33	1.04	0.98
PC 40:6; [M-Ac-H]-@6.69	ME206602	0.73	0.60	1.06	1.11	1.14	1.00	0.79	1.42	1.00	0.93
plasmenyl-PE 38:5; [M-H]-@6.74	ME206670	0.80	0.88	1.01	1.21	1.12	0.84	0.89	1.06	0.98	1.01
plasmenyl-PE 38:6; [M-H]-@6.51	ME206671	0.80	0.86	0.94	1.16	1.22	0.89	0.85	1.24	0.99	0.89
plasmenyl-PE 40:6; [M-H]-@7.17	ME206674	0.77	0.76	1.02	1.11	1.22	0.86	0.98	1.16	0.99	0.96
PC 38:5; [M-Ac-H]-@6.37	ME206594	0.75	0.65	1.03	1.24	1.02	0.92	0.89	1.17	1.05	1.05
PC 40:7; [M-Ac-H]-@6.22	ME206603	0.71	0.79	1.05	1.23	1.03	0.83	0.75	1.12	1.13	1.15
PC 35:2; [M-Ac-H]-@6.56	ME206579	0.86	1.09	0.97	1.10	0.98	0.80	0.98	1.08	1.03	1.16
PG 36:1; [M-H]-@6.45	ME206639	0.98	0.90	1.07	1.12	1.07	0.78	0.75	1.14	1.17	0.91
PC 38:3; [M-Ac-H]-@7.08	ME206592	1.04	1.02	1.28	0.98	1.04	0.72	0.86	1.14	0.90	0.89
CerP 34:2; [M-H]-@5.29	ME206546	0.99	1.03	1.19	1.01	0.98	0.68	0.90	1.08	1.03	1.08
PC 36:3; [M-Ac-H]-@6.40	ME206584	1.04	0.93	1.13	1.12	1.02	0.79	0.84	0.96	1.01	1.01
PC 33:2; [M-Ac-H]-@5.98	ME206572	1.00	1.27	0.84	1.13	0.97	0.90	0.91	0.96	1.28	0.83
PC 34:2; [M-Ac-H]-@6.21	ME206574	1.06	1.19	0.94	1.11	1.03	0.88	0.81	0.96	1.15	0.85
PC 37:4; [M-Ac-H]-@6.51	ME206589	0.65	1.11	0.98	1.26	1.01	0.94	0.88	1.03	1.05	0.88
PC 34:3; [M-Ac-H]-@5.76	ME206575	0.91	0.99	1.14	1.25	0.99	0.80	0.79	1.03	0.91	0.88
PC 38:2; [M-Ac-H]-@7.45	ME206591	1.02	0.99	1.06	1.19	0.91	0.91	0.95	1.01	0.88	0.90
plasmenyl-PE 38:2; [M-H]-@7.84	ME206667	0.88	1.20	0.95	1.36	1.06	0.74	0.80	1.01	0.86	0.95
PC 36:2; [M-Ac-H]-@6.85	ME206583	0.95	1.18	0.91	1.26	1.03	0.88	0.86	1.01	0.93	0.87
PG 36:0; [M-H]-@6.92	ME206638	0.89	1.16	0.91	1.17	1.10	0.97	0.98	0.98	0.86	0.85
plasmenyl-PE 42:6; [M-H]-@7.74	ME206676	0.91	1.03	1.05	1.00	0.92	0.94	1.23	1.21	0.84	0.90
PE 36:0; [M-H]-@7.84	ME206614	0.92	0.88	0.95	1.11	0.88	1.00	1.15	1.00	1.27	0.85
FFA(18:2)	ME206550	0.84	0.80	1.00	1.12	0.98	0.97	1.00	1.16	1.19	0.85
FFA(18:1)	ME206549	0.94	0.88	1.01	1.00	1.04	1.00	1.02	1.01	1.15	0.92
FFA(20:0)	ME206551	0.98	0.84	0.98	1.08	0.95	0.98	1.01	1.10	1.06	0.98
FFA(16:0)	ME206547	1.01	0.90	1.02	1.01	0.98	0.97	1.07	1.06	1.06	0.93
FFA(18:0)	ME206548	1.00	0.90	1.00	1.03	0.95	0.97	1.07	1.04	1.03	0.99
FFA(22:3)	ME206558	1.12	0.71	1.01	0.91	1.21	1.12	0.89	0.91	1.05	0.97
PC 32:0; [M-Ac-H]-@6.62	ME206568	1.16	0.81	1.05	1.00	0.99	1.03	0.87	1.01	1.14	0.85
CerP 32:1; [M-H]-@5.11	ME206544	0.81	0.87	1.22	1.21	1.25	0.93	0.69	1.11	0.67	0.76
PC 34:4; [M-Ac-H]-@5.53	ME206576	1.00	0.76	1.33	1.24	1.15	0.75	0.48	1.17	0.74	0.88
PC 32:2; [M-Ac-H]-@5.59	ME206570	1.04	1.11	1.08	1.37	0.99	0.75	0.67	1.08	0.80	0.77
PI 38:5; [M-H]-@5.38	ME206647	0.91	1.14	1.24	1.34	0.98	0.92	0.56	0.97	0.75	0.67
PC 30:1; [M-Ac-H]-@5.42	ME206567	1.13	1.31	1.13	1.27	1.02	0.72	0.60	1.05	0.60	0.89
PC 36:1; [M-Ac-H]-@7.27	ME206582	1.04	1.19	1.07	1.10	1.13	0.87	0.74	1.01	0.73	0.95
PC 32:1; [M-Ac-H]-@6.10	ME206569	1.26	1.08	1.19	1.05	1.12	0.99	0.59	0.80	0.77	0.86
PC 34:1; [M-Ac-H]-@6.65	ME206573	1.10	1.15	1.06	0.98	1.24	0.91	0.72	0.90	0.91	0.92
PI 40:5; [M-H]-@5.98	ME206648	1.19	1.10	1.09	0.92	1.16	1.09	0.61	0.94	0.88	0.87
PC 42:10; [M-Ac-H]-@5.71	ME206605	1.09	1.00	1.15	0.96	1.22	1.05	0.44	0.82	0.96	1.09
PI 38:3; [M-H]-@6.15	ME206645	1.06	1.15	1.03	1.08	1.22	0.99	0.42	0.86	1.00	1.00
PG 36:2; [M-H]-@6.02	ME206640	1.08	0.93	1.09	1.07	1.08	0.89	0.58	0.97	1.00	1.15
PC 40:4; [M-Ac-H]-@7.31	ME206600	1.02	1.03	1.03	1.14	1.29	0.80	0.61	0.90	0.86	1.10
PC 40:5; [M-Ac-H]-@7.06	ME206601	0.95	1.00	1.05	1.01	1.30	0.96	0.66	0.97	0.88	1.01
PI 38:4; [M-H]-@5.91	ME206646	0.96	0.98	0.98	1.18	1.13	1.15	0.56	0.95	0.98	0.85
PI 36:2; [M-H]-@5.93	ME206643	0.97	1.16	1.16	1.25	0.93	1.00	0.53	0.83	0.96	0.84
plasmenyl-PE 34:0; [M-H]-@7.20	ME206660	0.99	1.27	0.99	1.19	0.96	0.91	0.70	0.86	0.99	1.02
FFA(20:4) Arachidonic acid	ME206554	0.82	0.65	0.81	1.02	1.38	0.93	0.89	1.32	1.02	1.17
FFA(22:1)	ME206556	0.75	0.62	0.80	1.01	1.60	0.91	1.01	0.96	1.10	1.19
FFA(24:1)	ME206560	0.92	0.72	0.85	0.97	1.31	0.96	1.25	0.93	1.17	0.97
FFA(22:2)	ME206557	0.94	0.91	0.98	0.93	1.34	1.09	0.74	0.94	1.15	0.85
FFA(20:1)	ME206552	0.89	0.85	0.81	0.92	1.37	1.14	0.93	0.86	1.36	0.86
FFA(20:2)	ME206553	0.86	0.83	0.85	1.07	1.28	1.05	0.92	1.02	1.23	0.79
PC 40:3; [M-Ac-H]-@7.51	ME206599	0.83	0.54	1.27	0.91	1.05	0.87	0.91	0.93	1.29	1.26
lysoPE 20:4; [M-H]-@1.34	ME206656	0.90	0.70	0.84	1.10	1.24	0.81	0.87	0.82	1.26	1.51
lysoPE 22:6; [M-H]-@1.28	ME206658	1.03	0.57	0.86	1.09	1.12	0.97	0.70	1.17	1.31	1.22
lysoPE 22:5; [M-H]-@1.64	ME206657	1.15	0.71	1.04	1.05	1.28	0.90	0.80	0.72	0.85	1.33
plasmenyl-PE 38:3; [M-H]-@7.51	ME206668	0.91	0.95	1.24	0.94	1.18	0.63	0.60	0.87	1.12	1.47
plasmenyl-PE 34:3; [M-H]-@6.30	ME206662	0.93	0.72	1.07	1.10	1.29	0.76	0.54	1.16	0.95	1.27
plasmenyl-PE 36:1; [M-H]-@7.71	ME206663	0.93	0.95	1.18	1.04	1.29	0.69	0.67	0.97	0.80	1.27
plasmenyl-PE 38:4; [M-H]-@7.21	ME206669	0.91	0.90	1.09	1.06	1.23	0.75	0.64	1.01	0.97	1.29
plasmenyl-PE 32:1; [M-H]-@6.59	ME206659	1.09	0.92	0.96	1.16	1.42	0.68	0.85	0.68	1.15	0.93
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.46	ME206563	0.63	0.84	1.10	1.01	1.33	0.79	0.89	0.87	1.19	1.17
plasmenyl-PE 36:3; [M-H]-@6.90	ME206664	0.71	1.08	1.08	1.22	1.22	0.70	0.72	0.79	1.16	1.09
PS 38:4; [M-H]-@6.03	ME206650	1.47	0.66	1.61	0.65	0.77	0.85	0.73	1.18	0.51	1.49
PE 39:6; [M-H]-@6.49	ME206631	1.10	0.69	1.16	0.97	0.80	0.82	0.90	1.27	0.90	1.45
PE 40:8; [M-H]-@5.91	ME206636	0.73	0.69	1.52	1.00	0.65	0.74	0.93	1.07	0.72	1.73
PE 35:1; [M-H]-@7.07	ME206611	0.91	1.48	1.32	0.95	0.86	0.75	0.47	0.83	0.71	1.65
PE 39:4; [M-H]-@7.24	ME206630	1.04	0.48	1.33	1.16	1.01	0.88	0.44	0.70	1.07	1.45
PE 33:2; [M-H]-@6.05	ME206608	1.22	1.01	1.73	1.20	0.63	0.76	0.66	0.60	0.57	1.00
PI 36:1; [M-H]-@6.34	ME206642	1.02	1.03	1.48	0.99	1.18	0.86	0.49	0.69	0.83	0.95
PE 40:5; [M-H]-@7.14	ME206633	1.17	0.94	1.58	0.81	1.10	0.76	0.51	1.06	0.73	1.04
PE 40:6; [M-H]-@6.88	ME206634	1.10	0.83	1.50	0.85	1.08	0.94	0.61	1.05	0.84	0.85
PE 38:7; [M-H]-@5.73	ME206629	0.92	0.86	1.77	0.84	0.79	0.90	0.50	0.90	0.75	1.31
PE 40:7; [M-H]-@6.36	ME206635	0.90	0.73	1.54	1.05	0.83	0.90	0.71	0.91	0.78	1.21
PE 34:1; [M-H]-@6.84	ME206609	1.41	1.17	1.42	0.83	0.88	0.84	0.73	0.69	0.67	1.24
PE 36:3; [M-H]-@6.53	ME206617	1.25	1.23	1.32	1.04	0.93	0.68	0.76	0.63	0.75	1.24
PE 38:6; [M-H]-@6.11	ME206628	1.18	0.82	1.59	0.88	0.86	0.86	0.57	0.81	0.93	1.19
PE 36:4; [M-H]-@6.21	ME206618	1.25	0.93	1.54	0.87	0.99	0.75	0.70	0.69	0.82	1.16
PE 40:4; [M-H]-@7.40	ME206632	1.25	0.84	1.51	1.04	0.87	0.80	0.69	0.71	0.76	1.13
PE 36:1; [M-H]-@7.42	ME206615	1.06	1.07	1.41	1.01	0.96	0.83	0.58	0.74	0.75	1.26
PE 38:3; [M-H]-@7.22	ME206625	1.22	0.99	1.51	0.85	1.01	0.72	0.54	0.70	0.81	1.42
PE 38:5; [M-H]-@6.51	ME206627	1.17	0.90	1.56	0.96	0.97	0.78	0.50	0.64	0.76	1.37
lysoPE 16:0; [M-H]-@1.66	ME206651	1.06	0.72	0.80	0.97	1.07	0.73	0.96	1.20	0.95	1.87
lysoPE 18:0; [M-H]-@2.42	ME206652	0.91	0.55	0.82	1.03	0.89	0.66	0.88	1.43	0.90	2.30
lysoPE 18:1; [M-H]-@1.82	ME206653	0.91	0.98	0.79	1.01	1.41	0.73	0.69	0.72	0.98	1.93
lysoPE 18:2; [M-H]-@1.37	ME206654	1.13	1.20	0.68	1.07	1.31	0.75	0.73	0.79	1.16	1.43
lysoPE 20:3; [M-H]-@1.63	ME206655	1.31	0.92	0.94	0.97	1.49	0.58	0.48	0.90	1.01	1.46

Factors:

F1	Gender:female \| Glycemic status:Diabetic \| Neuropathy:Neuropathy
F2	Gender:female \| Glycemic status:Diabetic \| Neuropathy:no neuropathy
F3	Gender:female \| Glycemic status:Pre-diabetic \| Neuropathy:Neuropathy
F4	Gender:female \| Glycemic status:Pre-diabetic \| Neuropathy:no neuropathy
F5	Gender:male \| Glycemic status:Diabetic \| Neuropathy:Neuropathy
F6	Gender:male \| Glycemic status:Diabetic \| Neuropathy:no neuropathy
F7	Gender:male \| Glycemic status:Normoglycemic \| Neuropathy:Neuropathy
F8	Gender:male \| Glycemic status:Normoglycemic \| Neuropathy:no neuropathy
F9	Gender:male \| Glycemic status:Pre-diabetic \| Neuropathy:Neuropathy
F10	Gender:male \| Glycemic status:Pre-diabetic \| Neuropathy:no neuropathy

Data matrix